The standard annual wellness blood panel — CBC, chemistry panel, urinalysis — has not changed meaningfully in 15 years. It remains useful. It catches overt disease. But it was designed as a screening tool for conditions that are already producing measurable systemic effects, not for detecting conditions in the 6-18 month window before symptoms appear.
Adding biomarkers to an annual wellness visit is not about running every available test. It is about selecting additions based on the individual animal's age, breed, and condition risk. A blanket "expanded wellness panel" applied to every patient is more expensive and generates more incidental findings than targeted age-and-breed-based additions.
The Core Panel Gaps
What the standard chemistry panel misses at early disease stage:
- Creatinine for renal disease: Does not rise until 75% of nephron function is lost. A cat or dog with 50% functional kidney mass remaining looks normal on a standard panel.
- ALT for hepatic disease: Sensitive but not specific. Elevated ALT can reflect muscle damage, hemolysis, or drug effects. Does not identify fibrotic or cholestatic liver disease reliably at early stage.
- Total T4 for hypothyroidism: As discussed elsewhere, affected by systemic illness, drugs, and body condition. A single total T4 is a poor screening tool for hypothyroidism in the absence of clinical signs.
- Standard CBC for early neoplasia: Lymphoma is not visible on CBC until the disease is systemic. Hemangiosarcoma does not reliably produce anemia until the tumor is large or has bled.
Additions by Life Stage
Young adults (1-5 years, dogs; 1-7 years, cats)
For healthy young animals with no breed risk factors, the standard panel is generally adequate. The most cost-effective addition at this stage is a baseline measurement of SDMA and, in breeds with cardiac risk, NT-proBNP. These baseline values are clinically useful 3-5 years later when trend analysis becomes relevant — a rising SDMA means more when you know what the same animal's SDMA was at age 2.
Middle age (6-8 years, dogs; 8-12 years, cats)
This is where targeted additions have the highest yield. Specific recommendations by condition:
- Renal: Add SDMA and cystatin-C. Urinalysis with UPC ratio if SDMA is in the 14-18 µg/dL range.
- Cardiac (all breeds): Add NT-proBNP. For Dobermanns, Boxers, Great Danes: add cardiac troponin I and consider Holter referral if NT-proBNP is elevated.
- Thyroid (dogs): If clinical signs are present (weight gain, cold intolerance, bilateral alopecia, bradycardia), add free T4 by equilibrium dialysis rather than total T4. Total T4 as a wellness screen is not recommended in middle-aged dogs with any concurrent illness.
- Neoplasia (high-risk breeds): Goldens, Labs, Rottweilers, Bernese Mountain Dogs — annual neoplasia panel from age 5-6 onward. TK1, CRP, haptoglobin as minimum; full panel for breeds with 40%+ lifetime cancer incidence.
Seniors (9+ years, dogs; 12+ years, cats)
At this life stage, the question shifts from "what might develop" to "what is quietly progressing." Every senior pet should have:
- SDMA + cystatin-C (renal)
- NT-proBNP (cardiac)
- Fasting glucose + fructosamine (diabetes screening — subtle in cats, relevant for obese dogs)
- ACTH stimulation or LDDS test if clinical signs suggest Cushing's — not as a routine screen, but at lower threshold for clinical suspicion
- Blood pressure measurement — a separate but critical component of senior wellness that does not require a blood draw but is often omitted
For senior cats specifically: T4 screening is appropriate from age 10 onward given the high prevalence of hyperthyroidism in this demographic. Combined SDMA + cystatin-C + T4 in every wellness visit from 10 years covers the two most common life-limiting conditions in senior cats.
The Cost-Benefit Calculation
Owner reluctance to add tests to a wellness visit is often about cost. A reasonable approach that addresses this:
- Build targeted additions into age-specific wellness packages so the cost is predictable
- Explain the detection window: "This test can find kidney disease 12-18 months before your cat would show any symptoms" is more motivating than "your cat is getting older and we should test more things"
- Use the first year's results as baseline, which makes subsequent years' tests more valuable — owners who understand this are more willing to do annual panels consistently
The incremental cost of SDMA + NT-proBNP on a standard annual panel is typically $35-55 at reference lab pricing. The cost of diagnosing Stage 3 CKD rather than Stage 1 is measured in quality-of-life years, additional diagnostic workup, and more intensive ongoing management. The calculation is not close.